|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4828981A
(en)
|
1983-08-24 |
1989-05-09 |
Synbiotics Corporation |
Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
ES2052027T5
(es)
|
1988-11-11 |
2005-04-16 |
Medical Research Council |
Clonacion de secuencias de dominio variable de inmunoglobulina.
|
|
US5939272A
(en)
|
1989-01-10 |
1999-08-17 |
Biosite Diagnostics Incorporated |
Non-competitive threshold ligand-receptor assays
|
|
US5028535A
(en)
|
1989-01-10 |
1991-07-02 |
Biosite Diagnostics, Inc. |
Threshold ligand-receptor assay
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5922615A
(en)
|
1990-03-12 |
1999-07-13 |
Biosite Diagnostics Incorporated |
Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
|
|
CA2072758A1
(en)
|
1990-09-14 |
1992-03-15 |
Kenneth Francis Buechler |
Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
|
|
ATE177841T1
(de)
|
1991-04-10 |
1999-04-15 |
Biosite Diagnostics Inc |
''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
|
|
CA2107899A1
(en)
|
1991-04-10 |
1992-10-11 |
Gunars Edwin Valkirs |
Novel conjugates and assays for simultaneous detection of multiple ligands
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
US5885527A
(en)
|
1992-05-21 |
1999-03-23 |
Biosite Diagnostics, Inc. |
Diagnostic devices and apparatus for the controlled movement of reagents without membrances
|
|
US6143576A
(en)
|
1992-05-21 |
2000-11-07 |
Biosite Diagnostics, Inc. |
Non-porous diagnostic devices for the controlled movement of reagents
|
|
DK1975181T3
(da)
|
1992-10-28 |
2011-06-06 |
Genentech Inc |
Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
|
|
US5824799A
(en)
|
1993-09-24 |
1998-10-20 |
Biosite Diagnostics Incorporated |
Hybrid phthalocyanine derivatives and their uses
|
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
|
US6113855A
(en)
|
1996-11-15 |
2000-09-05 |
Biosite Diagnostics, Inc. |
Devices comprising multiple capillarity inducing surfaces
|
|
FR2756297B1
(fr)
|
1996-11-22 |
1999-01-08 |
Centre Nat Rech Scient |
Procede de production de virus recombinants
|
|
US5947124A
(en)
|
1997-03-11 |
1999-09-07 |
Biosite Diagnostics Incorporated |
Diagnostic for determining the time of a heart attack
|
|
EP1002078A1
(en)
|
1997-07-31 |
2000-05-24 |
Chiron Corporation |
Method enabling readministration of aav vector via immunosuppresion of host
|
|
ES2375931T3
(es)
|
1997-12-05 |
2012-03-07 |
The Scripps Research Institute |
Humanización de anticuerpo murino.
|
|
ATE454445T1
(de)
|
1998-11-10 |
2010-01-15 |
Univ North Carolina |
Virusvektoren und verfahren für ihre herstellung und verabreichung.
|
|
US6498244B1
(en)
|
1999-05-28 |
2002-12-24 |
Cell Genesys, Inc. |
Adeno-associated virus capsid immunologic determinants
|
|
US6399385B1
(en)
|
1999-09-29 |
2002-06-04 |
The Trustees Of The University Of Pennsylvania |
Methods for rapid PEG-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
|
|
DE60226641D1
(de)
|
2001-12-03 |
2008-06-26 |
Amgen Fremont Inc |
Antikörperkategorisierung auf der grundlage von bindungseigenschaften
|
|
PL2357189T3
(pl)
|
2003-06-19 |
2017-08-31 |
Genzyme Corporation |
Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US20060166363A1
(en)
|
2004-01-27 |
2006-07-27 |
Sergei Zolotukhin |
Modified baculovirus expression system for production of pseudotyped rAAV vector
|
|
CA2561686C
(en)
|
2004-03-31 |
2014-12-02 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
US7846445B2
(en)
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
KR101572700B1
(ko)
|
2007-06-07 |
2015-11-30 |
제넨테크, 인크. |
보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
|
|
MX2010001684A
(es)
|
2007-08-15 |
2010-04-21 |
Amunix Inc |
Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
|
|
CN108530543B
(zh)
|
2009-02-03 |
2023-06-23 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
|
AR080794A1
(es)
|
2010-03-26 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
|
|
MX2012014975A
(es)
|
2010-06-22 |
2013-03-12 |
Univ Colorado Regents |
Anticuerpos al fragmento c3d de componente 3 de complemento.
|
|
CA2865578C
(en)
|
2012-02-27 |
2023-01-17 |
Amunix Operating Inc. |
Xten conjugate compositions and methods of making same
|
|
JP6138018B2
(ja)
|
2013-10-03 |
2017-05-31 |
三菱電機株式会社 |
赤外線固体撮像素子
|
|
EA037120B1
(ru)
|
2015-02-02 |
2021-02-09 |
МЕИРЭДжТиЭкс ЮКей II ЛИМИТЕД |
Регулирование экспрессии генов посредством аптамер-опосредованного модулирования альтернативного сплайсинга
|
|
US20160346359A1
(en)
|
2015-05-01 |
2016-12-01 |
Spark Therapeutics, Inc. |
Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
|
|
JP6959912B2
(ja)
|
2015-09-23 |
2021-11-05 |
ジェネンテック， インコーポレイテッド |
抗ｖｅｇｆ抗体の最適化変異体
|
|
CA3019126A1
(en)
|
2016-03-30 |
2017-10-05 |
Spark Therapeutics, Inc. |
Cell line for recombinant protein and/or viral vector production
|
|
US20210371877A1
(en)
|
2017-12-18 |
2021-12-02 |
Spark Therapeutics, Inc. |
Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use
|
|
EP3784697A4
(en)
|
2018-04-27 |
2022-07-06 |
Spark Therapeutics, Inc. |
GMO AAV CAPSIDS WITH INCREASED TROPISM AND AAV VECTORS CONTAINING THE GMO CAPSIDS, AND METHODS FOR THEIR MANUFACTURE AND USE
|
|
JP2021522813A
(ja)
|
2018-05-07 |
2021-09-02 |
スパーク セラピューティクス インコーポレイテッドＳｐａｒｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
プラスミドを用いないａａｖベクター産生細胞株
|
|
CN112470003A
(zh)
*
|
2018-05-10 |
2021-03-09 |
曼彻斯特大学 |
评估黄斑变性的方法
|
|
BR112021009452A2
(pt)
|
2018-11-16 |
2021-08-17 |
Spark Therapeutics, Inc. |
ensaio in vitro para detectar intensificadores e inibidores de transdução de vetor de vírus adeno-associados (aav) e/ou detectar ou quantificar anticorpos de ligação a anti-aav
|